Savara (NASDAQ:SVRA) Stock Price Down 8.4% – What’s Next?

Savara Inc (NASDAQ:SVRA) shares dropped 8.4% during mid-day trading on Friday . The company traded as low as $2.95 and last traded at $2.95. Approximately 1,088,001 shares changed hands during mid-day trading, an increase of 14% from the average daily volume of 952,360 shares. The stock had previously closed at $3.22.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Savara in a research report on Friday, March 28th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $8.83.

Savara Trading Down 11.2 %

The company’s 50-day moving average is $2.90 and its 200-day moving average is $3.04. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The firm has a market cap of $494.06 million, a price-to-earnings ratio of -6.65 and a beta of 0.44.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The firm had revenue of $0.27 million during the quarter. On average, research analysts predict that Savara Inc will post -0.45 earnings per share for the current year.

Institutional Investors Weigh In On Savara

Institutional investors have recently modified their holdings of the business. Barclays PLC boosted its holdings in Savara by 217.5% during the third quarter. Barclays PLC now owns 231,005 shares of the company’s stock worth $979,000 after buying an additional 158,244 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Savara by 23.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 69,490 shares of the company’s stock valued at $295,000 after acquiring an additional 13,420 shares during the period. SG Americas Securities LLC boosted its stake in Savara by 14.0% during the 4th quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock worth $158,000 after acquiring an additional 6,330 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Savara by 14.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock valued at $112,000 after purchasing an additional 4,732 shares during the period. Finally, Rhumbline Advisers increased its stake in Savara by 6.8% in the fourth quarter. Rhumbline Advisers now owns 141,425 shares of the company’s stock valued at $434,000 after purchasing an additional 9,041 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.